证券代码：688621 证券简称：阳光诺和 公告编号：2025-108 北京阳光诺和药物研究股份有限公司 关于自愿披露对外投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、对外投资概述 （一）对外投资的基本情况 1 投资标的名称：上海弼领生物技术有限公司（以下简称"弼领生物"）。 投资金额：北京阳光诺和药物研究股份有限公司（以下简称"阳光诺和" 或"公司"）拟以自有资金出资 2,000 万元，认缴弼领生物新增注册资本 8.2661 万元，增资完成后将持有其 2.0435%的股权。 根据《上海证券交易所科创板股票上市规则》《公司章程》等规定， 本次投资无需提交董事会、股东会审议，已经公司总经理办公会审议 通过。 本次投资不构成关联交易，亦不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。 相关风险提示：投资标的实际经营过程中可能面临宏观经济及行业政 策变化、市场竞争等不确定因素的影响，存在一定的市场风险、经营 风险、管理风险等。敬请广大投资者注意投资风险。 为推进在新型纳米偶联药物和精 ...

Core Viewpoint - The company, 阳光诺和, is making a strategic investment of 20 million yuan in Shanghai Biling Biotechnology Co., aiming to enhance its position in the innovative drug industry, particularly in the field of novel nano-conjugated drugs and precise nano-delivery systems [1] Investment Details - The company will invest 20 million yuan to subscribe to an increase in registered capital of 82,661 yuan in Shanghai Biling Biotechnology, resulting in a 2.0435% equity stake [1] - This investment is part of the company's broader strategy to strengthen its innovative drug supply chain [1] Technology and Market Potential - Shanghai Biling Biotechnology specializes in novel nano-conjugated drugs and precise nano-delivery systems, which have significant application prospects in treating major diseases such as cancer [1] - The core technology platform of the target company can effectively enhance drug targeting and delivery efficiency, indicating a promising market potential [1] Strategic Alignment - The investment allows the company to enter the cutting-edge nano-drug technology sector, creating synergies with its existing business [1] - This move is expected to enrich the company's technological reserves and pipeline layout in innovative drug research and development, thereby enhancing its overall competitiveness in the pharmaceutical industry [1]

Core Viewpoint - The company, Sunlight Nuohe (688621.SH), is making a strategic investment of 20 million yuan in Shanghai Biling Biotechnology Co., Ltd. to enhance its position in the innovative drug industry, particularly in the field of novel nano-conjugated drugs and precise nano-delivery systems [1] Investment Details - The company will invest 20 million yuan to subscribe for an additional registered capital of 82,661 yuan in Biling Biotechnology, resulting in a 2.0435% equity stake in the company [1] - This investment is part of the company's broader strategy to strengthen its innovative drug industry chain [1] Technology and Market Potential - Biling Biotechnology specializes in novel nano-conjugated drugs and precise nano-delivery systems, which have significant application prospects in treating major diseases such as cancer [1] - The core technology platform of Biling can effectively enhance drug targeting and delivery efficiency, indicating a strong market potential [1] Strategic Alignment - The investment allows the company to enter the cutting-edge nano-drug technology sector, creating synergies with its existing business [1] - This move is expected to enrich the company's technological reserves and pipeline layout in innovative drug research and development, thereby enhancing its overall competitiveness in the pharmaceutical industry [1]

弼领生物成立于2021年5月，是一家专注于新型纳米偶联药物及精准纳米递送技术研发的生物科技企 业，组建了一支覆盖生物、化学、材料、工程、纳米技术等领域的多学科交叉研发团队，自主搭建起国 际首创的三大核心技术平台：纳米介导偶联药物技术平台、小分子-小分子自组装纳米技术平台、纳米 药物连续智造平台。依托上述平台，公司成功打通纳米药物从研发、转化到生产的全链条技术壁垒，并 凭借自主知识产权的高通量连续制造工艺与设备，实现纳米药物的逐级放大、质量稳定可控及连续化规 模化生产。 弼领生物以"新材料—新技术—新设备—新药物"四维融合为引擎，潜心雕琢"更有效、更安全、更便 捷、更经济"的突破性疗法，构建兼具全球差异化和引领性的新药管线，让更多的患者临床获益。弼领 生物已提交十余项发明专利，其中多项已在中、美、欧、日等地获权；多个候选药物正加速推进临床， 未来将持续刷新治疗标准。 格隆汇12月11日丨阳光诺和(688621.SH)公布，为推进在新型纳米偶联药物和精准纳米递送领域的整体 战略布局，公司拟以自有资金出资2,000万元，认缴弼领生物新增注册资本8.2661万元，增资完成后将持 有其2.0435%的股权。 ...

Core Viewpoint - Sunshine Nuohua (688621.SH) is advancing its strategic layout in the field of novel nano-conjugated drugs and precise nano-delivery by investing 20 million yuan to increase its stake in Biling Biotechnology [1] Group 1: Investment and Stake Acquisition - The company plans to use its own funds to invest 20 million yuan to subscribe to an increase in registered capital of 8.2661 thousand yuan in Biling Biotechnology, resulting in a 2.0435% equity stake [1] Group 2: Company Overview - Biling Biotechnology, established in May 2021, focuses on the research and development of novel nano-conjugated drugs and precise nano-delivery technologies [1] - The company has formed a multidisciplinary R&D team covering biology, chemistry, materials, engineering, and nanotechnology [1] Group 3: Technological Advancements - Biling Biotechnology has developed three core technology platforms: nano-mediated conjugated drug technology platform, small molecule-small molecule self-assembly nano-technology platform, and continuous intelligent manufacturing platform for nano-drugs [1] - The company has successfully established a full-chain technology barrier for nano-drugs from R&D to production, utilizing proprietary high-throughput continuous manufacturing processes and equipment [1] Group 4: Innovation and Clinical Development - Biling Biotechnology aims to create breakthrough therapies that are "more effective, safer, more convenient, and more economical" through a four-dimensional integration of new materials, new technologies, new equipment, and new drugs [1] - The company has submitted over ten invention patents, with several granted in regions such as China, the US, Europe, and Japan; multiple drug candidates are accelerating towards clinical trials [1]

人民财讯12月11日电，阳光诺和(688621)12月11日公告，公司拟以自有资金出资2000万元，认缴弼领生 物新增注册资本8.2661万元，增资完成后将持有其2.0435%的股权。弼领生物成立于2021年5月，是一家 专注于新型纳米偶联药物及精准纳米递送技术研发的生物科技企业，组建了一支覆盖生物、化学、材 料、工程、纳米技术等领域的多学科交叉研发团队。 ...

Core Viewpoint - The company plans to invest 20 million yuan in BiLing Bio to acquire a 2.0435% stake, enhancing its strategic positioning in the nanomedicine sector [1] Group 1: Investment Details - The investment will be made using the company's own funds to subscribe to an increase in registered capital of 82,661 yuan in BiLing Bio [1] - The investment has been approved by the company's general manager office meeting and does not constitute a related party transaction or a major asset restructuring [1] Group 2: Target Company Overview - BiLing Bio focuses on the research and development of novel nano-conjugated drugs and precise nano-delivery technologies [1] - In the previous year, BiLing Bio reported a revenue of 481,100 yuan and a net loss of 40,859,500 yuan [1] Group 3: Strategic Implications - This investment allows the company to enter the nanomedicine market, which is seen as a strategic opportunity [1] - However, the target company may face operational and market risks [1]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The 2025 National Medical Insurance and Commercial Health Insurance Innovation Drug Catalogs were released, adding 114 new drugs to the national insurance list, with a success rate of 88%, significantly higher than the previous year's 76% [2] - The first three quarters of 2025 saw a notable recovery in domestic innovative drug financing, with 324 financing events totaling $5.51 billion, a 67.6% increase year-on-year [3] - The flu positivity rate has not peaked yet, with a significant increase in flu cases, indicating a growing market for flu medications [4] - The report highlights breakthroughs in dual-target and new-target opportunities in the autoimmune field, with several companies making significant advancements [5] - There is a focus on inhalation formulations in respiratory diseases, with new drugs showing promising results [6] - Progress in liver-targeted small nucleic acids is noted, with companies like Arrowhead Pharmaceuticals making strides in this area [7] Summary by Sections 1. National Medical Insurance and Commercial Insurance Innovation Drug Catalogs - The 2025 catalog added 114 new drugs, including 50 innovative drugs, with a success rate of 88% [2] 2. Financing Trends and CXO Order Changes - Innovative drug financing events increased by 5.2% year-on-year, with total financing amounting to $5.51 billion [3] 3. Flu Positivity Rates - The flu positivity rate reached 51.1%, indicating a rising demand for flu medications [4] 4. Autoimmune Field Developments - Significant partnerships and advancements in dual-target drugs for autoimmune diseases were reported [5] 5. Inhalation Formulations in Respiratory Diseases - New inhalation drugs are showing positive clinical results, indicating a shift in treatment approaches [6] 6. Progress in Liver-Targeted Small Nucleic Acids - Arrowhead Pharmaceuticals achieved a milestone payment for its innovative RNA therapy, expanding its research pipeline [7] 7. Stock Recommendations - The report recommends stocks in various sectors, including inhalation formulations, small nucleic acids, and innovative drugs, highlighting specific companies for investment [8]

Core Points - The company has completed the deregistration of its subsidiary, Nanjing Nuohua Pharmaceutical Technology Co., Ltd. (Nuohua), as approved by the board on May 12, 2025 [1][2] - The deregistration process was finalized after receiving the registration notice from the Nanjing Jiangbei New District Administrative Approval Bureau [1] - The deregistration will not have a significant impact on the company's overall business development and profitability [2] Summary by Sections - **Deregistration Process** - The board of directors approved the deregistration of Nuohua on May 12, 2025 [1] - The company received the registration notice confirming the completion of the deregistration [1] - **Impact on Financials** - The consolidation scope of the company's financial statements will change, but it will not significantly affect the overall financial statements [2] - There are no adverse effects on the interests of the company and all shareholders, particularly minority shareholders [2]

证券代码：688621 证券简称：阳光诺和 公告编号：2025-107 北京阳光诺和药物研究股份有限公司 关于注销孙公司南京诺和欣医药科技有限公司暨关 联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于 2025 年 5 月 12 日召开第二届董事会第十九次会议，审议通过了《关 于注销孙公司南京诺和欣医药科技有限公司暨关联交易的议案》，同意注销控股 孙公司南京诺和欣医药科技有限公司（以下简称"诺和欣"）。具体内容详见公 司于 2025 年 5 月 13 日在上海证券交易所网站（www.sse.com.cn）披露的《北京 阳光诺和药物研究股份有限公司关于注销孙公司南京诺和欣医药科技有限公司 暨关联交易的公告》（公告编号：2025-042）。 近日，公司收到南京江北新区管理委员会行政审批局出具的《登记通知书》， 对诺和欣的注销登记申请予以登记，注销登记手续已办理完毕。 诺和欣注销完成后，不会对公司整体业务发展和盈利水平产生重大影响，公 司合并财务报表的范围将相应发生变化，但不会对公司合并财务报表产生较大影 ...